Stable: Does not qualify for CR, PR, Progression or Symptomatic Deterioration. All target measurable lesions must be assessed using the same techniques as baseline. d. Progression : One or more of the following must occur: 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Appearance of any new lesion/site. PSA increase by 25 % form baseline or nadir (whichever was smaller) and by ≥ 2 ng/mL at 12 weeks. Death due to disease without prior documentation of progression and without symptomatic deterioration.